Zhitong Finance App News, Shisi Pharmaceutical Group (02005) announced that the Group's stephenol dry suspension has completed the renewal of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2026)” (National Health Insurance Catalogue) and continues to be included in the new version of the National Health Insurance Catalogue.
The Group's stepentanol dry suspension (250 mg and 500 mg specifications) was approved in 2023, making it the first domestic model. This product was first included in the national health insurance catalogue in 2024. This product is a rare disease medication that matches the physiological characteristics of children. It is mainly used to treat severe myoclonic seizures (Dravet syndrome) in infants. Dravet syndrome is one of the types of epilepsy with poor prognosis as determined by the International Anti-Epilepsy Alliance. In 2018, it was included in the first batch of rare diseases in China. Before this product was approved, there was a lack of clinically targeted treatments, making it difficult for traditional anti-epileptic treatments to meet treatment needs. Children with Dravet syndrome require long-term standardized treatment. The dosage form of this product is suitable for young children with swallowing difficulties, and can balance medication adherence with individualized treatment needs. In addition, the Group's stephenol API has been approved as an API for use in marketed formulations, forming an integrated layout of raw materials and controllable costs.
In recent years, the Group has focused on clinical pain points such as inadequate adaptation of dosage forms for children and the difficulty of individualized and accurate dosage, and has continued to increase the development of suitable formulations, focusing on developing dosage forms suitable for children, such as dry suspensions, oral solutions, and granules, to promote the upgrading of children's medication. Focusing on anti-infection, respiratory system, digestive system, nervous system, etc., the group continuously enriches the pediatric drug product pipeline, continuously optimizes the design and taste of pediatric medication, and enhances the safety and compliance of children's medication. At the same time, the Group takes the initiative to connect with national health insurance negotiations, drug collection and other policies, and strives to promote more drugs that are urgently needed clinically and adapted to children to benefit patients and reduce the burden of medication use.